Evidence map›Paper›PMID 33528624›Full record

ArticleNeuroradiology2021

Clinical outcomes of isolated deep grey matter infarcts after endovascular treatment of large vessel occlusion stroke.

Johanna Ospel, Arnuv Mayank, Wu Qiu, Mohammed Almekhlafi, Bijoy Menon, Ryan McTaggart, Raul Nogueira, Andrew Demchuk, Manish Joshi, Charlotte Zerna and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroradiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 4 countries.

Johanna OspelClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Arnuv MayankClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Wu QiuClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Mohammed AlmekhlafiClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Bijoy MenonClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Ryan McTaggartInterventional Radiology, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Raul NogueiraNeurology, Emory University School of Medicine, Atlanta, GA, USA.
Andrew DemchukClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Manish JoshiClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Charlotte ZernaClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Rene ChapotNeuroradiology, Alfred Krupp Krankenhaus Essen, Essen, Germany.
Aditya BharathaSt. Michael's Hospital, Toronto, Canada.
Ashutosh JadhavUniversity of Pittsburgh, Pittsburgh, USA.
Simon NagelNeurology, University Hospital Heidelberg, Heidelberg, Germany.
Alexandre PoppeUniversite de Montreal, Montreal, Canada.
Michael TymianskiNoNo Inc., Toronto, Canada.
Michael HillClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Mayank GoyalClinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada. mgoyal@ucalgary.ca.ORCID http://orcid.org/0000-0001-9060-2109
ESCAPE-NA1 investigators
University of Calgary · CAAlfried Krupp Hospital · DEBrown University · USEmory University · USHeidelberg University · DENoNO (Canada) · CASt. Michael's Hospital · CAUniversité de Montréal · CAUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere are few data on the prevalence and impact of isolated deep grey matter infarction in acute stroke. In this study, we aimed to investigate the prevalence of isolated deep grey matter infarcts and their impact on the outcome.

methodsInfarcts on 24-h follow-up imaging (non-contrast head CT or diffusion-weighted MRI) in the ESCAPE-NA1 trial were categorized into predominantly deep grey matter infarcts vs. infarcts involving additional territories ("other infarcts"). Total infarct volume was manually segmented. Baseline characteristics and proportions of good outcome (primary outcome, defined as modified Rankin Score [mRS] 0-2 at 90 days), excellent outcome (mRS 0-1) and mortality were compared between patients with and without predominantly deep grey matter infarcts. Multivariable logistic regression with adjustment for baseline variables and total infarct volume was used to determine a possible association of predominantly deep grey matter infarcts and clinical outcome.

resultsPredominantly deep grey matter infarcts were seen in 316/1026 patients (30.8%). Compared to other patients, their ASPECTS was higher, collateral status and reperfusion quality were better and time to treatment was shorter. Good outcome was seen in 239/316 (75.6%) with vs. 374/704 (53.1%) without predominantly deep grey matter infarcts. After adjusting for baseline variables and total infarct volume, predominantly deep grey matter infarcts were independently associated with excellent outcome (

Indexed as

Arterial Occlusive DiseasesBrain IschemiaStrokeGray MatterHumansInfarctionTreatment OutcomeAcute ischemic strokeEndovascular therapyInfarctionIschemia

Identifiers

PMID33528624
OpenAlexW3127406246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.